Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 5/20 | 0.66 |
| ▸ | CDK2 | P24941 | 5/20 | 0.66 |
| ▸ | CDK1 | P06493 | 4/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27871148 | 0.85 | CDK1 (0.56) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL4022228 | 0.85 | CCNE1 (0.68) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL2916205 | 0.84 | HSP90AB1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL986731 | 0.83 | CDK1 (0.66) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL4022224 | 0.83 | CCNE1 (0.66) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL1377647 | 0.83 | CDK1 (0.76) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL24709725 | 0.81 | CCNE1 (0.72) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL21137280 | 0.81 | CCNE1 (0.72) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL3922885 | 0.81 | CDK1 (0.71) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL13870047 | 0.80 | CCNE1 (0.65) | CCNE1CDK2CDK1CCNB1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | CCNE1 518/4885CDK2 1276/4885CDK1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.